Quick Takeaways
- MRNA - Moderna, Inc. has 21 insiders with reported activity on this page.
- Net insider value flow over the last year: -$9,266,838.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 21 Insiders of Moderna, Inc.
- Symbol
- MRNA on Nasdaq
- Location
- Cambridge, MA
What Changed
- Buy value: ; sell value: $9,266,838.
- Net share flow: -198,563.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$9,266,838.
Buys
$0
Shares: 0
Insiders: 0
Sells
$9,266,838
Shares: 198,563
Insiders: 4
Net
-$9,266,838
Shares: -198,563
Insiders: -4
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 173,894 | $0 | $8,540,886 | -$8,540,886 |
| 3-6 | 0 | 24,357 | $0 | $717,216 | -$717,216 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 312 | $0 | $8,736 | -$8,736 |
Moderna, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Stephane Bancel | Chief Executive Officer, Director | $511,509,633 | Mixed | 01 Mar 2026 | ||
| Ph.D. Noubar B. Afeyan | Director | $183,139,027 | -$703,306 | -0.38% | Mixed | 11 Dec 2025 |
| Stephen Hoge | President | $87,303,959 | -$7,814,840 | -8.2% | Mixed | 27 Feb 2026 |
| Paul Sagan | Director | $15,693,665 | Mixed | 30 Apr 2025 | ||
| James M. Mock | Chief Financial Officer | $3,232,741 | Mixed | 02 Apr 2026 | ||
| Shannon Thyme Klinger | Chief Legal Officer | $2,674,429 | -$726,047 | -21% | Mixed | 05 Mar 2026 |
| Stephen Berenson | Director | $2,517,789 | Mixed | 03 May 2024 | ||
| Arpa Garay | Chief Commercial Officer | $1,524,005 | Mixed | 05 Dec 2023 | ||
| Juan Andres | Chief Technical Operations and Quality Officer | $1,330,232 | Mixed | 28 Dec 2022 | ||
| David W. Meline | Chief Financial Officer | $645,077 | Mixed | 09 Aug 2022 | ||
| Paul Burton | Chief Medical Officer | $541,865 | Mixed | 04 Nov 2022 | ||
| Elizabeth G. Nabel | Director | $193,267 | Mixed | 30 Apr 2025 | ||
| Sandra Horning | Director | $173,744 | Mixed | 30 Apr 2025 | ||
| David M. Rubenstein | Director | $133,707 | Mixed | 05 Aug 2025 | ||
| Abbas Hussain | Director | $107,441 | -$22,646 | -17% | Mixed | 09 Dec 2025 |
| Lori M. Henderson | General Counsel and Secretary | $93,614 | Mixed | 27 May 2021 | ||
| Elizabeth E. Tallett | Director | Mixed | 30 Apr 2025 | |||
| Robert Langer | Director | Mixed | 06 May 2024 | |||
| Jorge M. Gomez | Officer | Mixed | 09 May 2022 | |||
| Tal Zvi Zaks | Chief Medical Officer | Mixed | 30 Jun 2021 | |||
| Francois Nader | Director | Mixed | 30 Apr 2025 |
Top shareholders of Moderna, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
11%
|
41,584,782
|
$1,226,335,222 | — | 31 Dec 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
11%
|
41,301,469
|
$1,217,980,317 | +$393,401,259 | 30 Jan 2026 | |
| BlackRock, Inc. |
13F
|
Company |
8.4%
|
32,505,733
|
$958,594,060 | — | 31 Dec 2025 | |
| BAILLIE GIFFORD & CO |
13D/G
13F
|
Company |
5.3%
|
20,580,514
|
$814,988,354 | -$172,974,542 | 31 Dec 2025 | |
| Stephane Bancel |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
13,003,603
mixed-class rows
|
$511,509,633 | — | 01 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
4.2%
|
16,365,478
|
$482,617,946 | — | 31 Dec 2025 | |
| Capital World Investors |
13F
|
Company |
3.3%
|
12,828,040
|
$378,298,900 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.4%
|
9,219,644
|
$271,415,217 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.3%
|
8,870,716
|
$261,597,450 | — | 31 Dec 2025 | |
| Theleme Partners LLP |
13F
|
Company |
2.1%
|
8,081,810
|
$238,332,577 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
2%
|
7,729,700
|
$227,948,853 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.9%
|
7,342,096
|
$216,518,411 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
1.8%
|
7,029,694
|
$207,305,681 | — | 31 Dec 2025 | |
| Ph.D. Noubar B. Afeyan |
3/4/5
|
Director |
—
mixed-class rows
|
6,881,676
mixed-class rows
|
$183,139,027 | -$703,306 | 11 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.3%
|
5,182,759
|
$152,839,563 | — | 31 Dec 2025 | |
| Flagship Pioneering, LLC |
13F
|
Company |
1.2%
|
4,632,149
|
$136,602,075 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
1.2%
|
4,621,558
|
$136,289,758 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
1.1%
|
4,152,432
|
$122,455,220 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
1.1%
|
4,086,766
|
$120,518,730 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1%
|
3,950,619
|
$116,503,752 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.83%
|
3,228,531
|
$95,209,379 | — | 31 Dec 2025 | |
| BANQUE PICTET & CIE SA |
13F
|
Company |
0.81%
|
3,130,724
|
$92,325,051 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.77%
|
3,002,578
|
$88,546,025 | — | 31 Dec 2025 | |
| Stephen Hoge |
3/4/5
|
President |
—
mixed-class rows
|
1,924,742
mixed-class rows
|
$87,303,959 | -$7,814,840 | 27 Feb 2026 | |
| NORGES BANK |
13F
|
Company |
0.7%
|
2,702,832
|
$79,706,516 | — | 31 Dec 2025 | |
| Merck & Co., Inc. |
13F
|
Company |
0.59%
|
2,308,190
|
$68,068,523 | — | 31 Dec 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.56%
|
2,178,537
|
$64,245,055 | — | 31 Dec 2025 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0.56%
|
2,156,275
|
$63,588,550 | — | 31 Dec 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.5%
|
1,936,513
|
$57,107,768 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.46%
|
1,788,951
|
$52,775,104 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.45%
|
1,729,258
|
$50,995,821 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.42%
|
1,615,399
|
$47,638,116 | — | 31 Dec 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.41%
|
1,589,163
|
$46,864,418 | — | 31 Dec 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.4%
|
1,553,731
|
$45,819,527 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.4%
|
1,542,457
|
$45,487,053 | — | 31 Dec 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.39%
|
1,501,621
|
$44,282,797 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.35%
|
1,374,854
|
$40,544,443 | — | 31 Dec 2025 | |
| Douglas Lane & Associates, LLC |
13F
|
Company |
0.33%
|
1,291,465
|
$38,085,303 | — | 31 Dec 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.29%
|
1,143,780
|
$33,730,000 | — | 31 Dec 2025 | |
| Amundi |
13F
|
Individual |
0.29%
|
1,143,613
|
$33,725,147 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.29%
|
1,124,702
|
$33,167,463 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.29%
|
1,120,091
|
$33,031,484 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.26%
|
1,013,884
|
$29,899,458 | — | 31 Dec 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.25%
|
975,195
|
$28,758,501 | — | 31 Dec 2025 | |
| CAPITAL FUND MANAGEMENT S.A. |
13F
|
Company |
0.24%
|
937,080
|
$27,634,489 | — | 31 Dec 2025 | |
| Legal & General Group Plc |
13F
|
Company |
0.24%
|
936,970
|
$27,631,247 | — | 31 Dec 2025 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.06%
|
220,245
|
$26,927,000 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.19%
|
738,094
|
$22,869,948 | — | 31 Dec 2025 | |
| Sessa Capital IM, L.P. |
13F
|
Company |
0.19%
|
743,081
|
$21,913,459 | — | 31 Dec 2025 | |
| LETKO, BROSSEAU & ASSOCIATES INC |
13F
|
Company |
0.19%
|
726,440
|
$21,422,716 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Moderna, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| James M. Mock | MRNA | Common Stock | Tax liability | -1.2% | -703 | 57,748 | 02 Apr 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 2.55% | 1,453 | 58,451 | 02 Apr 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -33.3% | -1,453 | 2,906 | 02 Apr 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Tax liability | -7.98% | -5,704 | 65,782 | 05 Mar 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Options Exercise | 19.8% | 11,797 | 71,486 | 05 Mar 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Restricted Stock Units | Options Exercise | -8.33% | -11,797 | 129,774 | 05 Mar 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Tax liability | -9.1% | -5,704 | 56,998 | 05 Mar 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 23.2% | 11,797 | 62,702 | 05 Mar 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -8.33% | -11,797 | 129,774 | 05 Mar 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Sale | -18.9% | $726,047 | $52.29 | -13,885 | 59,689 | 02 Mar 2026 | Direct |
| Shannon Thyme Klinger | MRNA | Common Stock | Options Exercise | 23.3% | 13,885 | 73,574 | 02 Mar 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Stock Option (Right to Buy) | Options Exercise | -25% | -13,885 | 41,658 | 02 Mar 2026 | Direct | ||
| Stephane Bancel | MRNA | Stock Option (Right to Buy) | Award | 250,932 | 250,932 | 01 Mar 2026 | Direct | |||
| Stephen Hoge | MRNA | Restricted Stock Units | Award | 165,230 | 165,230 | 01 Mar 2026 | Direct | |||
| Stephen Hoge | MRNA | Stock Option (Right to Buy) | Award | 125,466 | 125,466 | 01 Mar 2026 | Direct | |||
| Shannon Thyme Klinger | MRNA | Restricted Stock Units | Award | 38,553 | 38,553 | 01 Mar 2026 | Direct | |||
| Shannon Thyme Klinger | MRNA | Stock Option (Right to Buy) | Award | 29,275 | 29,275 | 01 Mar 2026 | Direct | |||
| James M. Mock | MRNA | Restricted Stock Units | Award | 49,569 | 49,569 | 01 Mar 2026 | Direct | |||
| James M. Mock | MRNA | Stock Option (Right to Buy) | Award | 37,639 | 37,639 | 01 Mar 2026 | Direct | |||
| Stephen Hoge | MRNA | Common Stock | Tax liability | -1.3% | -19,260 | 1,457,763 | 27 Feb 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 2.74% | 39,830 | 1,495,950 | 27 Feb 2026 | Direct | ||
| Stephen Hoge | MRNA | Restricted Stock Units | Options Exercise | -100% | -39,830 | 0 | 27 Feb 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Tax liability | -8.13% | -4,837 | 54,647 | 27 Feb 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Options Exercise | 18.6% | 9,999 | 63,878 | 27 Feb 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Restricted Stock Units | Options Exercise | -100% | -9,999 | 0 | 27 Feb 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Tax liability | -10.5% | -5,323 | 45,393 | 27 Feb 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 24.6% | 11,004 | 55,693 | 27 Feb 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -89.3% | -11,004 | 1,315 | 27 Feb 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Sale | -9.89% | $7,814,840 | $48.84 | -160,009 | 1,457,427 | 23 Feb 2026 | Direct |
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 11% | 160,009 | 1,617,436 | 23 Feb 2026 | Direct | ||
| Stephen Hoge | MRNA | Stock Option (Right to Buy) | Options Exercise | -76.8% | -160,009 | 48,330 | 23 Feb 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Tax liability | -2.75% | -1,278 | 45,224 | 11 Feb 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Award | 5.99% | 2,630 | 46,502 | 11 Feb 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Tax liability | -2.39% | -1,334 | 54,527 | 11 Feb 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Award | 4.94% | 2,630 | 55,861 | 11 Feb 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Tax liability | -0.16% | -2,362 | 1,457,427 | 11 Feb 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Award | 0.34% | 4,884 | 1,459,789 | 11 Feb 2026 | Direct | ||
| Stephane Bancel | MRNA | Common Stock | Tax liability | -0.09% | -5,450 | 6,187,791 | 11 Feb 2026 | Direct | ||
| Stephane Bancel | MRNA | Common Stock | Award | 0.18% | 11,271 | 6,193,241 | 11 Feb 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Tax liability | -1.75% | -780 | 43,872 | 05 Jan 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 3.36% | 1,452 | 44,652 | 05 Jan 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -25% | -1,452 | 4,359 | 05 Jan 2026 | Direct | ||
| Ph.D. Noubar B. Afeyan | MRNA | Common Stock | Sale | -85.9% | $703,306 | $29.48 | -23,853 | 3,924 | 11 Dec 2025 | By Flagship Pioneering, Inc. |
| Ph.D. Noubar B. Afeyan | MRNA | Common Stock | Options Exercise | 607.9% | 23,853 | 27,777 | 11 Dec 2025 | By Flagship Pioneering, Inc. | ||
| Ph.D. Noubar B. Afeyan | MRNA | Stock Option (Right to Buy) | Options Exercise | -100% | -23,853 | 0 | 11 Dec 2025 | By Flagship Pioneering, Inc. | ||
| Stephane Bancel | MRNA | Common Stock | Options Exercise | 12.5% | 688,073 | 6,181,970 | 11 Dec 2025 | Direct | ||
| Stephane Bancel | MRNA | Stock Option (Right to Buy) | Options Exercise | -100% | -688,073 | 0 | 11 Dec 2025 | Direct | ||
| Abbas Hussain | MRNA | Common Stock | Sale | -25% | $13,910 | $27.60 | -504 | 1,515 | 09 Dec 2025 | Direct |
| James M. Mock | MRNA | Common Stock | Tax liability | -34.6% | -22,817 | 43,200 | 05 Dec 2025 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 250.6% | 47,190 | 66,017 | 05 Dec 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.